In MCF-7 cells, TNFa induces a G1 arrest with an increased expression of p21/Waf1, an activation of NF-kB and an accumulation of p53. NF-kB and p53 are two transcriptional factors known to activate p21/Waf1 gene expression. Here we show that p53 inhibition has no effect on p21/Waf1 mRNA accumulation following TNFa treatment. In contrast, inactivation of NF-kB inhibits p21/Waf1 expression without affecting G1 arrest. The fact that p21/Waf1 gene expression is still stimulatedwhenp53isinactivatedstronglysuggeststhatTNFa induces accumulation of an inactive form of p53 protein. This assumption was further supported by the following observations: (i) the p53 DNA-binding activity to its consensus sequence was not stimulated following TNFa treatment, (ii) phosphorylation at Ser-15, -20 or -392 was not detected in response to TNFa, (iii) the transcription rate of Ddb2, another p53 target gene, was not stimulated by TNFa. Finally, the accumulation of p53 in the nuclei of TNFa-treated MCF-7 cells was concomitant with an increase in p53 mRNA level, suggesting a regulation at the transcription level.
Introduction
To respond and adapt to changes in its external environment, such as exposure to growth factors, cytokines or stressinducing stimuli such as ionising radiation, the cell must initiate a program of regulated gene expression. This response depends on many factors such as the cell type and the number and intensity of the new stimuli. To a large extent these changes are mediated by nuclear DNA-binding proteins, which function in a combinatorial manner to activate or repress the transcription of target genes. Many cellular stimuli result in activation of both the tumour suppressor p53 and NF-kB.
TNFa initiates a broad range of cellular responses including growth stimulation of various non-transformed cell lines (e.g. fibroblasts), and, in contrast, G1-growth arrest of many other transformed cell lines (e.g. the human breast carcinoma MCF-7) or apoptosis.
1 ± 4 At a molecular level, TNFa binds the TNF receptor and induces its trimerization. The ligand-bound activated TNF receptor associates with the cytoplasmic adaptor protein TRADD, which functions as a platform to recruit several signalling molecules (reviewed in 5 ). The active TNF receptor complexes can interact with caspase proteases via TRADD and FADD to induce apoptosis. 6, 7 TNF receptor complexes also interact, via TRADD, with TRAF2 and RIP proteins, which are involved in the activation of JNK/AP-1 and NF-kB. 6 ± 9 Different studies have shown that TNF-activated NF-kB plays an anti-apoptotic role against TNF cytotoxicity. 10, 11 In fact, NF-kB regulates a set of anti-apoptotic genes including members of the Bcl-2 family, cellular inhibitors of apoptosis protein (c-IAP2 and c-IAP1), A20 and superoxide dismutase 2 (SOD2) (reviewed in 12 ). Interestingly, NF-kB also regulates the expression of the tumour suppressor gene p53, 13 although the role of this regulation is not well understood. 14, 15 A large number of evidence places the p53 suppressor gene at a nodal point in the regulation of diverse stress responses. Indeed, a number of cellular stresses including DNA damage, heat shock, hypoxia, hyperoxia, metabolic changes, oncogene activation, and others, converge on p53 protein and cause its activation and stabilization. 16 p53 is a transcription factor which exerts its function mainly through binding to a specific DNA responsive element. Activation of p53 by post-translational events (reviewed in 17 ) increases the affinity of the protein for its DNA consensus sites, leading to an increased expression of a set of target genes. Accumulation of the protein generally results from an extended half-life brought about by post-translational modifications that could be distinct from those involved in p53 activation. 18 But accumulation of p53 could also arise from an up-regulation of its gene transcription rate. 13 A number of p53-regulated genes are associated with induction of apoptosis or cell cycle arrest. 19 One of the most important is the p21/Waf1 gene, an inhibitor of several cyclin-dependent kinases, and a target for diverse signals that induce growth arrest and differentiation. While p53 is not required for induction of p21/Waf1 transcription during development and in most tissues of the adult mouse, the p53-dependent regulation of p21/Waf1 is critical for the response to DNA damage (reviewed in 20 ) . Activation of p53 following exposure to DNA damage caused by UV-or girradiation or chemotherapeutic agents leads to p53-dependent transcription of p21/Waf1. Cells without functional p53 cannot induce p21/Waf1. 21 However, there is accumulating evidence that the expression of the p21/Waf1 gene can be induced upon stimulation through a pathway, which does not require p53 (reviewed in 20 ). Kobayashi et al. showed an increased rate and accumulation of p21/ Waf1 in TNFa-treated cells expressing a transcriptioninactive p53 mutant. 22 In contrast, Jeoung et al reported that in MCF-7 cells induction of p21/Waf1 protein is closely related to p53 induction. Based on their results, they suggested that induction of p21/Waf1 protein by TNFa is mediated by p53. 4 By analyzing the response to TNFa of cell lines derived from MCF-7 and expressing either the HPV E6 or DD protein, two p53 inhibitors, or IkBa, an inhibitor of NF-kB, we provide evidence that p21/Waf1 is not regulated by p53 but by NF-kB in TNFa-treated MCF-7 cells. This observation leads us to demonstrate that TNFa induces accumulation but not activation of p53.
Results
Induction of p21/Waf1 gene expression in MCF-7 following TNFa treatment is independent of p53 expression
In agreement with published data, 23, 24 results reported in Figure 1A show that treatment of MCF-7 cells with TNFa (10 ng/ml) resulted in a transient arrest of cells at the G0/G1 phase followed by apoptosis. The cyclin-dependent kinase inhibitor p21/Waf1 is one regulator of the cell cycle that can cause cell growth arrest. 25 Under our experimental conditions, in MCF-7/E6 cells prevents the accumulation of p53 protein in TNFa-treated cells but is without effect on the increased expression of p21/Waf1. Following incubation with TNFa for the indicated times, volumes of cellular extract corresponding to 10 mg of total proteins were loaded on a 10% (for p53 detection) or 12% (for p21/Waf1 detection) SDS-polyacrylamide gel and analyzed by Western blot using the antibodies DO-7 to reveal p53 and anti p21/Waf1 (Ab1 from Calbiochem) to reveal p21/Waf1 p21/Waf1 mRNA was significantly increased by TNFa, 4 h after treatment ( Figure 1B ). These results corroborate those obtained by Jiang and Porter. 24 Previous results have indicated that p53 accumulation preceded activation of p21/ Waf1 in response to TNFa 4 suggesting a causal relationship between p53 activation, p21/Waf1 stimulation and G1 arrest. To test the possible implication of p53 in p21/Waf1 accumulation in TNFa-treated MCF-7 cells, the induction of p21/Waf1 gene expression by TNFa was tested in MCF-7/E6, a MCF-7 derived cell line stably transfected with a cDNA encoding HPV16/E6 protein. 26 Expression of E6 protein in MCF-7/E6 cells has been shown to impair the p53-dependent p21/Waf1 accumulation induced by g-radiation. 26 The viral protein E6 promotes p53 degradation by the ubiquitination pathway. 27 This degradation accounts for the lower steadystate level of p53 protein in MCF-7/E6 as compared to MCF-7/ neo ( Figure 1C, t0) . This difference was enhanced following TNFa treatment, which significantly increased the p53 protein level in MCF-7 cells but not in MCF-7/E6 cells ( Figure 1C, t4  and 16 ). Unexpectedly, p21/Waf1 mRNA ( Figure 1B and C) and protein ( Figure 1D ) levels were increased in TNFa-treated MCF-7/E6 as strongly as in MCF-7/neo, suggesting that TNFa induces p21/Waf1 accumulation via a p53-independent pathway. To confirm these results, we established the MCF-7/DD-TO cell line, a MCF-7 derived cell line engineered to exhibit a tetracycline inducible expression of p53DD, a dominant negative truncated p53 mutant. Two independent clones were analyzed in parallel. As already reported, 28 the p53DD expression stabilizes MCF-7-endogenous wt-p53 ( Figure 2A , lanes`+tet'), but inhibits its transcriptional activity as shown by transient expression of luciferase reporter gene under the control of a p53 responsive element ( Figure 2B ). However, the p53DD expression ( Figure 2C , lanes`+tet') had no effect on the increase of p21/Waf1 mRNA level brought by TNFa treatment. These results further support the assumption that TNFa stimulates the p21/Waf1 gene expression by a p53-independent pathway. p21/Waf1 expression is regulated by NF-kB in response to TNFa
In response to diverse signals that induce growth arrest and differentiation, p21/Waf1 is regulated at a transcription level by a number of distinct transcription factors, besides p53 (reviewed in 20 ) . Recently it was shown that, in TNFa-treated Ewing tumour cells, the stimulation of p21/Waf1 expression is dependent on NF-kB activation. 29 We then asked whether, in TNFa-treated MCF-7 cells, the NF-kB activation could account for the p53-independent stimulation of p21/Waf1.
Under our experimental conditions, NF-kB was already strongly induced in the 15 min following TNFa addition to MCF-7 ( Figure 3A ) and this activation was prolonged for at least 16 h ( Figure 6B , middle panel). We then analyzed, in both MCF-7 and MAD-1904, the effect of 4-and 16-h TNFa-treatment on p21/Waf1 mRNA expression. MAD-1904 is a stable transformant of MCF-7 expressing the IkBa(A32/36) mutant, a superrepressor form of IkBa 30 which behaves like a constitutive repressor of NF-kB activity.
31 SOD2 gene that is known to be regulated by TNFa through an intronic NF-kB element, 32 was used as a positive control. 33 As expected, TNFa treatment significantly increased the level of SOD2 mRNA in MCF-7 but not in MAD-1904 ( Figure 3B ). Similarly, p21/Waf1 expression was severely impaired in MAD-1904 cells, strongly suggesting that NF-kB activation accounts for the upregulation of p21/Waf1 gene expression in MCF-7 cells in response to TNFa-treatment. To reinforce this assumption further, NF-kB was inactivated using a chemical inhibitor, sodium salicylate (NaSal). 34 A 30-min pre-incubation of MCF-7 cells with 5 mM or 20 mM NaSal was followed by a 16-h incubation with TNFa. As shown in Figure 3C , 20 mM NaSal abrogated the TNFa-induced SOD2 expression and both the endogenous and TNFa-induced expression of p21/ Waf1, showing that NF-kB does account for the TNFadependent up-regulation of p21/Waf1 in MCF-7 cells. These results confirm and extend to MCF-7 those obtained by Javelaud et al., 29 showing that in MCF-7, like in Ewing tumour cells, the regulation of p21/Waf1 transcription depends on NF-kB. A functional NF-kB binding site within the p21/Waf1 gene remains to be identified to prove definitely that the p21/Waf1 gene is directly transactivated by NF-kB.
TNFa-dependent G1-arrest is independent of NF-kB activation
To examine further the implication of NF-kB-mediated activation of p21/Waf1 gene expression in TNFa-induced G1 arrest, the percentage of cells in G1 was evaluated comparatively by flow cytometry in both MCF-7/neo and MAD-1904 cells. Cells were treated in parallel with a mitotic inhibitor, the nocodazole. 35 This allows identification of the true G1-arrest cell population (cells unable to proceed through S-phase) as illustrated in Figure 4A by comparing panels A1 versus A4, and B1 versus B4. Addition of nocodazole to the culture medium considerably increases the G2/M peak. But, in MCF-7 TNFa-treated cells there is only a modest increase in G2/M peak in the presence of nocodazole ( Figure 4A , compare panels A3 and A4). This result clearly illustrates the TNFa-induced G1 arrest. This G1 arrest is equally observed with MAD-1904 ( Figure 4A , compare panels A6 and A8), suggesting that TNFa-specific G1 arrest is not dependent on NF-kB-mediated induction of p21/Waf1 gene expression. This conclusion was further supported by analyzing the levels of p21/Waf1 protein comparatively in MCF-7/neo and MAD-1904. As expected, the extent of p21/ Waf1 protein accumulation in TNFa-treated MCF-7/neo cells is not affected by nocodazole treatment ( Figure 4B 
p53 is not activated by TNFa
The fact that p21/Waf1 gene expression is not stimulated by p53 in response to TNFa in MCF-7 strongly suggests that the The induction of p21/WAF1 and SOD2 gene expression following TNFa treatment is impaired in MAD1904 cells. Total RNA was extracted from MCF-7/neo and MAD1904 cells either mock-treated or treated with TNFa for 4 h or 16 h before RNA extraction. Twenty mg of RNA were electrophoresed in 1% agarose-6% formadehyde gel and transferred to nylon membrane (Hybond N, Amersham) by electrophoresis. The blot was successively hybridized with p21/WAF1, SOD2, and GAPDH cDNA probes. (C) Sodium salicylate (NaSal) abrogated the TNFa-mediated stimulation of p21/WAF1 gene expression. MCF-7 cells were mock-treated or treated with the indicated amount of NaSal. After 30 min of incubation, cells were mocktreated or treated with 10 ng/ml TNFa for 16 h. p21/WAF1, SOD2 and GAPDH expression was analyzed as described in B increase in p53 protein level is not concomitant with its activation. To further support this assumption, the effect of TNFa on p53-transcriptional activity was checked by analyzing the expression of Ddb2, a recently identified p53 target gene that encodes for the p48 subunit of a human damagespecific DNA binding protein. 36 As expected, Ddb2 expression is stimulated in response to g irradiation in MCF-7/neo but is not in MCF-7/E6 cells. Yet, the expression of this gene is not stimulated in response to TNFa treatment ( Figure 5) , showing again that TNFa-mediated induction of p53 gene expression is not accompanied by its transcriptional activation. To better understand the lack of p53-target gene stimulation following the induction of wt-p53 accumulation in TNFa-treated MCF-7 cells, the affinity of p53 for its DNA responsive element was measured by electromobility shift assays (EMSA). Nuclear extracts of MCF-7 cells, mock-treated or treated with 10 ng/ml of TNFa for 1.5, 3 and 16 h, were incubated with doublestrand DNA sequences containing a binding site either for p53, NF-kB or Sp1 transcription factors. The p53 binding site used consists in a perfect p53 DNA responsive element, with two adjacent consensus decamers (Pu Pu Pu C A/T T/A Py Py Py). Adriamycin was used as a positive control for p53 activation. As expected, an intense band corresponding to the complex [DNA/p53/PAb421] was obtained with adriamycin- 3, and 4) . On the contrary, and in agreement with published data, 37 both adriamycin and TNFa activated the specific DNA-binding activity of NF-kB ( Figure  6B , middle panel, compare lane 1 to lanes 2, 3, 4 and 5). The Sp1 binding activity that was stimulated neither by adriamycin nor by TNFa treatment was used as a negative control ( Figure  6B , bottom panel). To insure that the difference in p53-specific DNA binding activity of cellular extracts treated either with adriamycin or TNFa did not simply reflect a lower level of p53 accumulation in TNFa-versus adriamycin-treated cells, p53 concentration was evaluated by an ELISA assay. Indeed, the p53 concentration was increased by a factor 8 in adriamycin treated-cells and by only a factor 2 in TNFa-treated cells (data not shown and Figure 8 ). DNA band-shift assay was then repeated by adjusting the volume of adriamycin-and TNFatreated cellular extracts to have an equivalent amount of p53 in each DNA-binding reaction mixture. Results presented in Figure 6 , show a significant activation of p53-specific DNA binding activity in adriamycin-treated cellular extract even with a p53 concentration equivalent to that of untreated or TNFatreated cellular extracts (panel C2, compare lanes 1 and 2 to lane 3). From these results, we conclude that TNFa is not able to activate the MCF-7-endogenous wt-p53. This observation was extended to two other cell lines derived from tumours of different origins, but expressing wild-type p53. Similarly to the results obtained with MCF-7, TNFa did not activate specific DNA binding activity of the endogenous wt-p53 expressed either in Hep G2, a cell line derived from a hepatocellular carcinoma ( Figure 6B , upper panel, compare lane 6 with lanes 7, 8, and 9), or in U-2 OS, a cell line derived from an osteosarcoma ( Figure 6B , upper panel, compare lane 11 with lanes 12, 13, and 14) . These results demonstrated that the specific DNA-binding activity of wt-p53 is not stimulated by TNFa, at least in the three cell lines tested. p53 accumulates within the nuclei of TNFa-treated cells Nuclear localization of p53 has been shown to be essential for the activity of p53 protein. 38 In normal, non-stressed cells, p53 sub-cellular localization is variable and depends on the phase of the cell cycle. p53 is predominantly nuclear from approximately mid G1 to G1/S transition, then becomes increasingly cytoplasmic as the cell progresses through the cell cycle. 39 Similar regulation of p53 intracellular localization through the cell cycle progression has been described for MCF-7. 40 We then checked if p53 nuclear exclusion could account for the accumulation of an inactive form of p53 in cells treated with TNFa. TNF-treated or untreated MCF-7 cells were subjected to cell fractionation, and p53 protein contents in both nuclear and cytoplasmic fractions were evaluated by Figure 7A . p53 protein was not detectable in mock-treated cells, nor in the cytoplasmic or nuclear fractions. As expected, p53 accumulated in the nuclei of g-irradiated cells. Comparable results were obtained in response to TNFa treatment. A p53 band was easily detectable in the nuclear but not in the cytoplasmic fraction of cells incubated in the presence of TNFa for 4 and 16 h. We conclude that nuclear exclusion cannot account for the fact that p53 is transcriptionally inactive in TNFa-treated cells.
TNFa treatment does not induce p53 phosphorylation at Ser-15, -20 and -392, in MCF-7 cells
The C-and N-terminal domains are exposed to covalent posttranslational modifications (phosphorylation, acetylation, sumoylation) that modulate p53 activity (reviewed in 17, 41 ). In particular, depending on the stress, phosphorylation at Ser-15 and -20 in the N-terminal region and -392 in the C-terminal region participate to p53 activation and/or stabilization. 42 The fact that TNFa treatment led to an accumulation of a transcriptional inactive form of p53 prompts us to analyze the phosphorylation state of p53 in TNFa-treated cells. Adriamycin treatment that activates p53 was used as a positive control. p53 phosphorylation was revealed by Western blot using antibodies directed against phosphorylated Ser-15, -20 or -392. As expected, the adriamycin treatment induced p53 phosphorylation at these three sites ( Figure 7, panel B1 ). Phosphorylation at Ser-20 and Ser-392 occurred earlier (1 ± 2 h after adding adriamycin) than phosphorylation at Ser-15, which was detectable only 8 h after the addition of adriamycin to the culture medium. In contrast, no phosphorylated form of p53 was revealed in TNFa-treated MCF-7 cells (Figure 7, panel B2) . As already mentioned, the p53 concentration is lower in TNFa-than in adriamycin-treated cells (compare the intensity of the bands revealed by DO-7 in panel B1 and B2). To ensure that no detection of p53 phosphorylated forms in TNFa-treated cellular extracts was not a bias imputable to the limit of antibody sensitivity, Western blot were performed by loading an equivalent amount of whole p53 protein. Results are presented in Figure 7 for a 16 h treatment with either adriamycin (panel B1, lane 7b) or TNFa (B2, lane 7b). Although the DO-7-band intensity was comparable in both cases, again there was no specific band revealed by antibody directed against the phosphorylated forms of p53 in TNFatreated cell extracts. We conclude that, in contrast to adriamycin treatment, TNFa leads to accumulation of a p53 protein non-phosphorylated at position 15, 20 and 392.
Concomitant increase of p53 protein and mRNA levels in MCF-7, in response to TNFa
The promoter sequences of the p53 gene contains binding elements for transcription factors that may regulate expression in response to defined stimuli, including motifs for AP1, NF-kB and Myc/Max/USF. 43 The fact that TNFa activated NFkB makes p53 gene a good candidate to be transcriptionally regulated by TNFa. We then quantified, at different times following the addition of TNFa to the culture medium, the Figure 8 show that TNFa had doubled the level of p53 mRNA 16 h after the addition of TNFa. Interestingly, the time-courses of p53 mRNA and protein accumulation are comparable in terms of kinetics and magnitude. This observation suggests that TNFa-induced accumulation of p53 protein results from a higher rate of transcription rather than from a stabilization of the protein.
All taken together, these results demonstrate that TNFa induces the accumulation of an inactive form of p53 by regulating the p53 transcription level.
Discussion
In this paper, we show that TNFa induces the expression of both p53 and p21/Waf1 in MCF-7 cell line. We provide evidence that NF-kB but not p53 is involved in the regulation of p21/Waf1 by showing that NF-kB but not p53 inactivation impairs TNFa-induced stimulation of p21/Waf1 expression. This led us to demonstrate that TNFa induces the accumulation of an inactive form of p53 unable to bind specifically to DNA and to activate the expression of its target genes. Consistent with this assumption, we report that Ser-15, Ser-20, and Ser-392 are not phosphorylated in response to TNFa. It is well documented that phosphorylation at Ser-15 and Ser-392 up-regulates the p53's transcriptional activity. 44 The notion that p53 accumulation could be dissociated from its activation has already been proposed. Chernov et al. 18 showed that PKC inhibitors induce an increase in p53 lifetime without inducing p53 activation. Tryptic digestion of stabilized protein shows that although PKC inhibitor decreases the overall level of p53 phosphorylation, this treatment leads to the appearance of a new set of phosphopeptides, leading the authors to propose that accumulation and activation of p53 could result from distinct phosphorylation events.
In our cellular model, both p53 mRNA and protein levels increased in parallel, strongly suggesting that the rate of p53 gene transcription could account for the accumulation of p53 protein. Indeed the p53 promoter contains a functional NF-kB site 43 supporting the hypothesis that the increase level of p53 mRNA could arise from the TNFamediated NF-kB activation. In this line of evidence, it was previously reported that p53 gene expression is activated through NF-kB after Benzo(a)pyrene treatment. 15 The idea that p53 accumulation results from a higher transcription rate rather than from the protein stabilization is emphasised by the fact that TNFa did not induce p53 phosphorylation at Ser-20. Indeed, phosphorylation at Ser-20 has been shown to inhibit p53 interaction with the ubiquitin-ligase MDM2, preventing p53 degradation by the proteasome pathway and thereby promoting p53 stabilization. 50 Some papers describe the existence of an emerging PKR/p53 pathway involved in TNF-induced apoptosis (reviewed in 45 ). It has been demonstrated that the TNFainducible kinase PKR can phosphorylate p53 in vitro at serine 392. 46 Phosphorylation of serine 392 has been shown, in vitro, to convert p53 to an active form, 47 suggesting that TNFa could activate p53 through PKR. Our results argue against this interpretation since we did not detect p53 modification at serine 392 in TNFa-treated cells. Alternatively, PKR, which has been reported to activate NF-kB (reviewed in 48 ), could participate in the increase of p53 gene expression. In support of this notion, it was demonstrated that p53 mRNA expression level is increased in PKR-overexpressing cells. 49 On the other hand, NF-kB inactivation, which diminishes the expression of p21/Waf1, has no effect on TNFadependent G1-arrest. This fact would imply that p21/Waf1 is not involved in the G1 arrest induced by TNFa. We can not exclude, however, the possibility that a very low remaining expression of p21/Waf1 could account for the G1-arrest identified in TNFa-treated MAD-1904 cells. In different cellular models, other investigators have found that p21/Waf1 is not required to induce G1-arrest in response to TNFa. Shiohara et al. 51 have shown that overexpression of p21/Waf1 antisense in ME-180 cells does not abrogate TNFa-dependent G1-growth arrest. Additionally, Nalca and Rangnekar 52 have demonstrated that interleukin-1 (IL-1), another cytokine promoting cytostatic effects, induces p53 and p21/Waf1 expression. However, and in agreement with our results with TNFa, cells in which p53 and p21/Waf1 have been switched off are still arrested in the G1-phase following IL-1 incubation. 52 These results raise the question of the pathway by which cytokines such as TNFa or IL-1, could induce G1-arrest. In preliminary experiments, we showed that the product of the retinoblastoma gene (Rb) is under-phosphorylated in response to TNFa (data not shown). Rb has been implicated in the regulation of the cell cycle through its interaction with the transcription factor E2F. Dephosphorylated Rb interacts with E2F, leading to functional inhibition of this protein that is essential for cellcycle progression (reviewed in 53 ). In the hypothesis of an inhibition of Rb phosphorylation by TNFa, G1 arrest would depend on the maintenance of hypo-phosphorylated forms of Rb rather than on p21/Waf1 overexpression or p53 activation.
Although TNFa-induced p21/Waf1 accumulation seems not to be involved in G1 arrest, it might play an antiapoptotic role against TNFa-induced apoptosis. Indeed, it has been shown that expression of an antisense of p21/ Waf1 sensitizes MCF-7 cells to TNFa-dependent apoptosis. 24 Consistent with this, cytoplasmic accumulation of p21/Waf1 observed during monocytic differentiation is concomitant with a resistance to various apoptotic stimuli including TNFa. 54 Therefore, it will be interesting to analyze the MCF-7 sub-cellular localization of p21/Waf1 in response to TNFa.
In conclusion, we show that TNFa stimulates the expression of both p21/Waf1 and p53, in MCF-7 cells, and that the TNFa-related stimulation of p21/Waf1 is dependent on NF-kB activation. The accumulation of p53 that arises from an increase of p53 gene transcription, could also depend on TNFa-mediated activation of NF-kB. Although TNFa leads to the accumulation of a transcriptional inactive form of p53, it cannot be excluded that p53 accumulation could be involved in TNFa-dependent induction of apoptosis. Indeed, it has been reported that p53 can induce apoptosis independently of its transactivation properties (reviewed in 55 ). Moreover, some published results suggested an implication of p53 in TNFa-dependent apoptosis. 35, 56 We are presently analyzing the possible relationship between p53 accumulation and TNFa-induced apoptosis.
Materials and Methods

Cells and treatment
The cells U-2 OS (derived from a human osteosarcoma), MCF-7 (derived from a human breast carcinoma) and Hep G2 (derived from a human hepatocellular carcinoma) express wt-p53. MCF-7/MAD1904 cells, expressing IkBa, the dominant negative of NF-kB 35 and MCF-7/ E6, expressing HPV16/E6 protein 26 were a gift from S Chouaib. MCF-7/DD-TO cell lines were derived from MCF-7 using the tetracyclineregulated mammalian expression (T-Rex TM ) system from Invitrogen. T-Rex TM System uses regulatory elements from the E. coli Tn10-encoded tetracycline (Tet) resistance operon. In this system, expression of the gene of interest is repressed in the absence and induced in the presence of tetracycline. MCF-7 cells were first stably transfected with pcDNA6/TR, which encodes the Tet repressor (TetR) under the control of the human CMV promoter. The TetR-expressing cell line was then stably transfected with pDDm-TO, a tetracycline inducible expression vector obtained by inserting the sequence that encodes the mouse p53DD truncated protein, into the Invitrogen vector, pcDNA4/TO/B. The p53DD truncated protein includes the mouse p53-amino acid residues 1 ± 14 and 302 ± 390. 57 Transfections were performed according to the manufacturer's protocol.
All cells were maintained at 378C in DMEM containing 10% foetal calf serum (FCS). MCF-7/MAD1904 and MCF-7/E6 cell lines were cultured in the presence of 0.2 mg/ml of geneticin (Gibco BRL). The p53DD protein expression was induced by adding tetracycline to the medium (1 mg/ml). All the treatments were performed 48 h after plating (3.10 6 cells per 10 cm Petri dish), except otherwise indicated. TNFa (Sigma) was added to a final concentration of 10 ng/ml. Sodium salicylate was added at the indicated concentration for 30 min before adding TNFa (10 ng/ml), and incubated for an additional 16 h. Adriamycin (10 mg/ml, Sigma) was added for 16 h. The cells were exposed to g irradiation at a dose of 6 Gy and a dose rate of 2.0 Gy/ min, using a 137 Cs source (IBL 637 apparatus, Cisbio International).
Northern blot
Northern-blot analysis was performed as described. 28 Preparation of the probes has been described. 58 
Western blot
Western blots were performed as described. 58 Whole p53 protein was detected using DO-7 or PAb122 supernatant hybridomas, the phosphorylated forms using anti-phosphop53 Ser-15, -20, and -392 from Cell Signaling technology. The p21/Waf1 protein was revealed with the anti-p21/Waf1 (Ab1) from Calbiochem.
Cell fractionation
Cells were scraped, washed and lysed in buffer A (20 mM HEPES, pH 7.6, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 20% glycerol, 4 mM Pefabloc) containing 0.1% NP-40. The lysate was centrifuged for 5 min at 5006g. Supernatant was collected and centrifuged at 100 0006g for 1 h at 48C. Soluble material which represents the cytosol fraction, was conserved at 7808C, while the pellet was resuspended in ice-cold sucrose buffer I (320 mM sucrose, 3 mM CaCl 2 , 2 mM MgCl 2 , 0.1 mM EDTA, 10 mM Tris-base, pH 8.0, 1 mM DTT, 0.1% NP-40). The resuspended pellet was loaded on a cushion of sucrose buffer II (2 mM sucrose, 5 mM MgCl 2 , 0.1 mM EDTA, 10 mM Tris-base, pH 8.0, 1 mM DTT) and centrifuged at 30 0006g at 48C for 45 min. The pellet (nucleus) was washed twice in buffer A and nuclear proteins were extracted using the same buffer containing additionally 0.5 M NaCl. Then, nuclear and cytosol fraction (30 mg of total protein) were separated on a 10% gel SDS ± PAGE and p53 was detected by Western blot.
EMSA
Nuclear extracts were prepared as described. 58 For p53 DNA binding analysis, nuclear extract (10 mg of total protein) was incubated with 0.4 ng of 32 P-labelled self-renatured palindromic probe [TCGACGGA-CATGCCCGGGCATGTCC] (the underlined nucleotides correspond to the consensus sequence). Complexes were resolved on a 4% native acrylamide gel or on a PhastGel gradient 4 ± 15% (Amersham Pharmacia biotech) as described. 58 For Sp1 and NF-kB DNA binding analysis, nuclear extract (5 mg of total protein) was incubated with Sp1 and NF-kB-32 P-labelled consensus probes, and complexes were separated on a 4% or 6% non-denaturing acrylamide gel, respectively. Sp1 and NF-kB probes were purchased from Promega.
ELISA
Cells were scraped, washed twice with ice-cold PBS and lysed for 30 min at 48C in buffer containing 50 mM Tris-base (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% NP40 and 1 mM Pefabloc (Boehringer Mannheim). Solubilized extracts were collected after centrifugation for 15 min at 10 0006g. Total protein concentration was determined by the Bradford assay (Biorad Protein Assay). The p53 and p21/Waf1 protein concentrations in extract were estimated using the`p53 pan ELISA' kit (Roche Molecular Biochemicals) and the`Waf1 ELISA' kit (Oncogene Research Product), respectively.
Cell cytometry analysis
MCF-7 cells were collected, washed with PBS and then fixed in 70% ethanol. After 16 h at 7208C, cells were washed with PBS and then incubated for 30 min at 378C in 0.5 ml of PBS containing 50 mg/ml propidium iodide and 50 mg/ml RNAse A. Cell DNA content was evaluated by flow cytometry using a FacScan (Becton Dickinson).
Luciferase assay
Luciferase assays were performed as previously reported using the pE1B-hWaf1 plasmid, which contains the human Waf1-p53 responsive element cloned upstream the luciferase gene. 59 Real-time quantitation mRNA p53 mRNA was quantified using the TaqMan apparatus (Perkin Elmer Biosystems), while p21/Waf1 and Ddb2 mRNAs were quantified using Lightcycler apparatus (Roche Molecular Biochemicals).
For p53 quantification, cDNA synthesis was performed in a volume of 20 ml using TaqMan reverse transcription reagents (Perkin Elmer Biosystems, Foster City, USA), as previously described. 60 For the b- . PCR was performed as previously described. 60 The use of VIC and 6-FAM reporter dye on the b-actin and p53 probes, respectively, allowed quantification from a multiplex PCR reactions.
Results are normalized to b-actin. For p21/Waf1 and Ddb2 mRNA quantification, cDNA synthesis was performed using oligo dT (Sigma) and AMV reverse transcriptase as described by the manufacturer (Promega). Real-time quantitative PCR was done using the`FastStart DNA Master SYBR Green' kit (Roche Molecular Biochemical 
